Delving into the Latest Updates on Influenza A virus H5N1 vaccine(CSL Ltd.) with Synapse

Overview

Basic Info

Drug Type

Prophylactic vaccine

Synonyms

Avian influenza (bird flu) virus vaccine - CSL, CSL444 (Pandemic ISCOMATRIX Flu), H5N1 aluminium pandemic influenza vaccine (CSL Ltd)

+ [6]

Target-

Mechanism

Immunostimulants

Therapeutic Areas

Infectious DiseasesRespiratory Diseases

Active Indication

Influenza, Human

Inactive Indication-

Originator Organization

CSL Ltd.

Active Organization

Seqirus UK LimitedSeqirus Ltd.

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

EU (18 Oct 2009),

Influenza, Human

Regulation-

Login to view timeline

The main purpose of this study is to assess the ability of H5 influenza virus vaccines and adjuvants present in the National Pre-Pandemic Influenza Vaccine Stockpile (NPIVS) to generate an immune response to homologous and to antigenically distant heterologous H5 influenza virus strains.
The study is designed to evaluate the safety and immunogenicity of vaccination strategies with homologous or antigenically distant heterologous H5 influenza virus vaccines administered with AS03 or MF59 adjuvant.

Start Date15 Mar 2018

Sponsor / Collaborator

Biomedical Advanced Research and Development Authority (BARDA)

NCT00478816 / CompletedPhase 2

A Phase II, Single Center, Exploratory Study to Evaluate Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Adults Unprimed and Primed With MF59-adjuvanted or Non-adjuvanted H5N3 Influenza Vaccines

Valuate the immune response and reactogenicity of H5N1 vaccination in a primed population (H5N3 adjuvanted or non-adjuvanted vaccine) compared to immunologically naïve subjects

Start Date01 May 2007

Sponsor / Collaborator-

NCT00376402 / CompletedPhase 2

Phase II Study of a Pandemic Influenza Vaccine in Elderly Participants

The World Health Organisation has warned that an influenza pandemic is inevitable. The avian influenza H5N1 virus strain is one of the leading candidates to cause the next influenza pandemic. The elderly are likely to be a special target group for vaccination; therefore, this study will test the safety and immunogenicity of a H5N1 pandemic influenza vaccine in a healthy elderly population.

Start Date01 Oct 2006

Sponsor / Collaborator

Seqirus GmbH

100 Clinical Results associated with Influenza A virus H5N1 vaccine(CSL Ltd.)

Login to view more data

100 Translational Medicine associated with Influenza A virus H5N1 vaccine(CSL Ltd.)

Login to view more data

100 Patents (Medical) associated with Influenza A virus H5N1 vaccine(CSL Ltd.)

Login to view more data

23

Literatures (Medical) associated with Influenza A virus H5N1 vaccine(CSL Ltd.)

01 Oct 2021·Nanomedicine: Nanotechnology, Biology and MedicineQ2 · MEDICINE

RNA-dependent assembly of chimeric antigen nanoparticles as an efficient H5N1 pre-pandemic vaccine platform

Q2 · MEDICINE

Article

Author: Cheong, Yucheol ; Jang, Yo Han ; Chae, Wonil ; Kim, Young-Seok ; Lim, Jongkwan ; Seo, Sang-Uk ; Seong, Baik L ; Hwang, Beom Jeung ; Roh, Young Hoon ; Lee, Jinhee

Highly pathogenic avian influenza viruses (HPAIVs) pose a significant threat to human health, with high mortality rates, and require effective vaccines. We showed that, harnessed with novel RNA-mediated chaperone function, hemagglutinin (HA) of H5N1 HPAIV could be displayed as an immunologically relevant conformation on self-assembled chimeric nanoparticles (cNP). A tri-partite monomeric antigen was designed including: i) an RNA-interaction domain (RID) as a docking tag for RNA to enable chaperna function (chaperna: chaperone + RNA), ii) globular head domain (gd) of HA as a target antigen, and iii) ferritin as a scaffold for 24 mer-assembly. The immunization of mice with the nanoparticles (~46 nm) induced a 25-30 fold higher neutralizing capacity of the antibody and provided cross-protection from homologous and heterologous lethal challenges. This study suggests that cNP assembly is conducive to eliciting antibodies against the conserved region in HA, providing potent and broad protective efficacy.

01 Jul 2021·CellQ1 · BIOLOGY

The single-cell epigenomic and transcriptional landscape of immunity to influenza vaccination

Q1 · BIOLOGY

Article

Author: Maecker, Holden T ; Chang, Sarah E ; Ashuach, Tal ; Rouphael, Nadine ; Utz, Paul J ; van der Most, Robbert ; Cheung, Peggie ; Foecke, Mariko Hinton ; Davis, Mark ; Pulendran, Bali ; Li, Chunfeng ; De Jong, Sanne E ; Wimmers, Florian ; Bosinger, Steven E ; Gupta, Shakti ; Cortese, Mario ; Kuo, Alex ; Subramaniam, Shankar ; Dvorak, Mai ; Yosef, Nir ; Hagan, Thomas ; Donato, Michele ; Khatri, Purvesh

Emerging evidence indicates a fundamental role for the epigenome in immunity. Here, we mapped the epigenomic and transcriptional landscape of immunity to influenza vaccination in humans at the single-cell level. Vaccination against seasonal influenza induced persistently diminished H3K27ac in monocytes and myeloid dendritic cells (mDCs), which was associated with impaired cytokine responses to Toll-like receptor stimulation. Single-cell ATAC-seq analysis revealed an epigenomically distinct subcluster of monocytes with reduced chromatin accessibility at AP-1-targeted loci after vaccination. Similar effects were observed in response to vaccination with the AS03-adjuvanted H5N1 pandemic influenza vaccine. However, this vaccine also stimulated persistently increased chromatin accessibility at interferon response factor (IRF) loci in monocytes and mDCs. This was associated with elevated expression of antiviral genes and heightened resistance to the unrelated Zika and Dengue viruses. These results demonstrate that vaccination stimulates persistent epigenomic remodeling of the innate immune system and reveal AS03's potential as an epigenetic adjuvant.

01 Apr 2019·Archives of VirologyQ4 · MEDICINE

Analysis of the efficacy of an adjuvant-based inactivated pandemic H5N1 influenza virus vaccine

Q4 · MEDICINE

Article

Author: Makbuz, Amanzhol ; Kassenov, Markhabat ; Sansyzbay, Abylay ; Renukaradhya, Gourapura J ; Volgin, Yevgeniy ; Khairullin, Berik ; Rametov, Nurkuisa ; Sagymbay, Altynay ; Tabynov, Kaissar ; Nurpeisova, Ainur

This paper describes a preclinical study analyzing the immunogenicity and protective efficacy of Kazfluvac^®, an adjuvant-based inactivated pandemic influenza A/H5N1 virus vaccine. In this study, laboratory animals (ferrets and mice) were vaccinated by the intramuscular or intraperitoneal route at an interval of 14 days with two doses of the vaccine containing different concentrations of influenza virus hemagglutinin (HA) protein. HA protein without adjuvant (aluminum hydroxide and Merthiolate) was used as a control. As a negative control, we utilized PBS. We assessed the protective efficacy of the candidate vaccine by analyzing the response to challenge with the influenza virus strain A/chicken/Astana/6/05 (H5N1). Our experimental results revealed substantially reduced clinical disease and an increased antibody response, as determined by hemagglutination-inhibition (HAI) test and microneutralization assay (MNA). This study showed that the candidate vaccine is safe and elicits an antigen-dose-dependent serum antibody response. In summary, we determined the optimum antigen dose in a Kazfluvac^® adjuvant formulation required for induction of heightened immunogenicity and protective efficacy to mitigate H5N1 disease in experimental animals, suggesting its readiness for clinical studies in humans.

100 Deals associated with Influenza A virus H5N1 vaccine(CSL Ltd.)

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	Influenza A virus H5N1 vaccine(CSL Ltd.)	J07BB01	-

R&D Status

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Influenza, Human	NO	Seqirus Ltd.	18 Oct 2009
Influenza, Human	LI	Seqirus Ltd.	18 Oct 2009
Influenza, Human	EU	Seqirus Ltd.	18 Oct 2009
Influenza, Human	IS	Seqirus Ltd.	18 Oct 2009